Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?

Company Overview - Allogene Therapeutics (ALLO) shares have increased by approximately 52.2% over the past month, outperforming the S&P 500 [1] - The stock currently holds a Zacks Rank 3 (Hold), indicating an expectation of in-line returns in the upcoming months [4] Earnings Estimates - Estimates for Allogene Therapeutics have been trending upward over the past month, suggesting positive sentiment among analysts [2][4] - The stock has an aggregate VGM Score of F, with a Growth Score of D, a Momentum Score of B, and a Value Score of F, placing it in the bottom 20% for the value investment strategy [3] Industry Performance - Allogene Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Halozyme Therapeutics (HALO) has gained 12.4% over the past month [5] - Halozyme Therapeutics reported revenues of $264.86 million for the last quarter, reflecting a year-over-year increase of 35.2%, with an EPS of $1.11 compared to $0.79 a year ago [6] - Halozyme is expected to post earnings of $1.17 per share for the current quarter, indicating a year-over-year change of 28.6%, with a Zacks Rank 2 (Buy) and a VGM Score of A [7]